Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Net Margin (2016 - 2025)

Viridian Therapeutics, Inc.\DE has reported Net Margin over the past 12 years, most recently at 89575.0% for Q4 2025.

  • Quarterly results put Net Margin at 89575.0% for Q4 2025, up 2079861.0% from a year ago — trailing twelve months through Dec 2025 was 481.22% (up 8875653.0% YoY), and the annual figure for FY2025 was 481.23%, up 8880189.0%.
  • Net Margin for Q4 2025 was 89575.0% at Viridian Therapeutics, Inc.\DE, down from 49.67% in the prior quarter.
  • Over the last five years, Net Margin for VRDN hit a ceiling of 49.67% in Q3 2025 and a floor of 134313.33% in Q2 2025.
  • Median Net Margin over the past 5 years was 66806.94% (2023), compared with a mean of 54954.94%.
  • Biggest five-year swings in Net Margin: plummeted -6495647bps in 2023 and later skyrocketed 8889684bps in 2025.
  • Viridian Therapeutics, Inc.\DE's Net Margin stood at 13526.17% in 2021, then plummeted by -222bps to 43604.76% in 2022, then tumbled by -112bps to 92593.06% in 2023, then dropped by -19bps to 110373.61% in 2024, then increased by 19bps to 89575.0% in 2025.
  • The last three reported values for Net Margin were 89575.0% (Q4 2025), 49.67% (Q3 2025), and 134313.33% (Q2 2025) per Business Quant data.